Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04901884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Jun 1, 2026 → Sep 1, 2027
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary and study completion pushed from Jun 1, 2026 to Sep 1, 2027 Interventions: PET/MR with 18F-FDG (Drug) to PET/MR with 18F-FDG (Drug) · Eligibility criteria expanded, about 10 words Show 2 more changesShow less
    • Interventions: PET/MR with 18F-FDG (Drug) to PET/MR with 18F-FDG (Drug)
    • Eligibility criteria expanded, about 10 words
  2. Primary and study completion dates: Jun 1, 2025 to Jun 1, 2026v6
  3. Primary and study completion dates: Jun 2024 to Jun 1, 2025v5
  4. Primary and study completion dates: Jun 2023 to Jun 2024v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jun 2021 to Jun 1, 2021v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2021 to Jun 1, 2021
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH). Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose. To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Trial Details
NCT Number NCT04901884
Lead Sponsor University Health Network, Toronto
Conditions Pulmonary Hypertension
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov